Trial Profile
Gemzar (gemcitabine) and Alimta (pemetrexed) in the treatment of patients with recurrent platinum-sensitive and platinum-resistant ovarian or peritoneal cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2005
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.